Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

The question for investors is not whether OTTAVA tin go a viable product, but whether Johnson & Johnson (NYSE:JNJ) tin person its differentiated plan and broader surgical portfolio into meaningful marketplace share, and adjacent situation Intuitive Surgical (ISRG) successful the process.

Bull Case for Johnson & Johnson (JNJ)

OTTAVA's astir compelling diagnostic is its table-integrated architecture. Johnson & Johnson (NYSE:JNJ) stated that the robotic arms are incorporated straight into the operating table, which allows the strategy to inhabit 30% to 50% little abstraction than accepted boom- and cart-mounted systems. The institution believes this plan could marque robotic country accessible to operating rooms that antecedently could not accommodate a larger platform. That gives Johnson & Johnson (NYSE:JNJ) a perchance differentiated selling constituent among hospitals focused connected operating-room capableness and workflow efficiency.

The FDA authorized OTTAVA for aggregate upper-abdominal wide country procedures, including gastric bypass, gastrectomy, cholecystectomy, gastric sleeve surgery, appendectomy, and hiatal hernia repair. Johnson & Johnson (NYSE:JNJ) volition commercially motorboat the OTTAVA strategy with prime customers successful the United States to absorption connected aboriginal lawsuit occurrence and simultaneously beforehand the exertion into further regulatory jurisdictions and indications gradually. In addition, it has an ongoing U.S. objective proceedings for OTTAVA successful inguinal hernia procedures.

The selective motorboat is strategically sensible due to the fact that robotic country systems necessitate respective factors for their creaseless functioning successful summation to regulatory authorization, including grooming for surgeons and operating-room staff, integration of the strategy into existing workflows, and establishing process volumes capable to warrant the investment. With specified a measured rollout, Johnson & Johnson (NYSE:JNJ) has clip to cod real-world feedback, amended training, and refine the level earlier attempting a broader commercialized expansion.

J&J besides brings advantages that smaller robotic-surgery challengers whitethorn lack. Its surgical portfolio already includes wound-closure products, stapling systems, instruments, and different operating-room technologies. That existing beingness could supply commercialized entree to hospitals and surgeons arsenic the institution introduces OTTAVA. However, the grade to which J&J tin construe those relationships into robotic-system placements remains unproven.